

### SRC Publications

1. Namey E, Agot K, **Ahmed K**, Odhiambo J, **Skhosana J**, Guest G and Corneli A. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. **Culture, Health & Sexuality** 2016. DOI: 10.1080/13691058.2016.1164899
2. Corneli A, Perry B, McKenna K, Agot K, **Ahmed K**, Taylor KJ, Malamatsho F, Odhiambo J, **Skhosana J** and Van Damme L. Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. **J Acquired Immune Deficiency Syndrome** 2016. 71 (4): 452-461.
3. Corneli A, Yacobson I, Agot K and **Ahmed K**. Guidance for Providing Informed-Choice Counseling on Sexual Health for Women Interested in Pre-Exposure Prophylaxis in Kenya and South Africa. **AIDS Patient Care STDS**. 2016. *Published ahead of print*.
4. Deese J, Masson L, Miller W, Cohen M, Morrison C, Wang M, **Ahmed K**, Agot K, Crucitti T, Abdellati S and Van Damme L. Injectable Progestin-Only Contraception is Associated with Increased Levels of Pro-Inflammatory Cytokines in the Female Genital Tract. **American Journal of Reproductive Immunology**. 2015; 74 (4): 357-367.
5. **Malahleha M**, **Ahmed K**, Deese J, Nanda K, Van Damme L, De Baetselier I and Burnett RJ. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report. **Journal of Medical Case Reports** 2015; 9: 207. DOI 10.1186/s13256-015-0679-4.
6. Friedland BA, Stoner M, Chau MM, Plagianos MG, Govender S, Morar N, Altini L, Skoler-Karppoff S, **Ahmed K**, Ramjee G, **Monedi C**, Maguire R and Lahteenmaki P. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial. **Aids and Behaviour** 2015. DOI 10.1007/s10461-015-1123-x.
7. Corneli A, Namey E, **Ahmed K**, Agot K, **Skhosana J**, Odhiambo J and Guest G. Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. **Aids Patient Care and STDs** 2015; 29 (9): DOI: 10.1089/apc.2015.0038
8. Corneli A, Field S, Namey E, Agot K, **Ahmed K**, Odhiambo J, **Skhosana J** and Guest G. Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP. **PloS One** 2015; DOI:10.1371/journal.pone.0129177.

9. Kelly CA, Friedland BA, Morar NS, Katzen LL. , Ramjee G, Mokgatle MM and **Ahmed K**. Tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa. **Culture, Health & Sexuality** **2015**. DOI: 10.1080/13691058.2015.1030451.
10. Agot K, Taylor D, Corneli A, Wang M, Ambia J, Kashuba A, Parker C, Lemons A, **Malahleha M**, Lombaard J, Van Damme L. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. **AIDS Behav.** **2015**; 19 (5): 743-751.
11. Corneli A, Perry B, Agot K, **Ahmed K**, Malamatsho F and Van Damme L. Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial. Plos One **2015**. DOI:10.1371/journal.pone.0125458.
12. Corneli A. L, McKenna K, Perry B, **Ahmed K**, Ago K, Malamatsho F, **Skhosana J**, Odhiambo J, Van Damme L. The Science of Being a Study Participant: FEM-PrEP Participants' Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills. **J Acquired Immune Deficiency Syndrome** **2015**; 68 (5): 578-584.
13. Parker C, Corneli A, Agot K, Odhiambo J, Asewe J, **Ahmed K**, **Skhosana J**, Rathagana M, Lanham M, Wong C, Deese J, Manongi R, Van Damme L . Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial. **Open Access Journal of clinical Trials** **2015**; 7: 1-9.
14. Callahan R, Nanda K, Kapiga S, **Malahleha M**, Mandala J, Ogada T, Van Damme L, Taylor D, for the FEM-PrEP Study Group. Pregnancy and Contraceptive Use Among Women Participating in the FEM-PrEP Trial. **Acquir Immune Defic. Syndr** **2015**; 68 (2): 196 – 203.
15. Mandala J, Nanda K , Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, **Malahleha M**, Manongi R, Taylor D and Van Damme L. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. **BMC Pharmacology and Toxicology** **2014**; 15 (1): 77.
16. Corneli A, Wang M, Agot K, **Ahmed K**, Lombaard J, Van Damme L, for the FEM-PrEP Study Group. Perception of HIV Risk and Adherence to a Daily, Investigational Pill for HIV Prevention in FEM-PrEP. **Journal of Acquired Immune Deficiency Syndromes** **2014**; 67 (5): 455-575.
17. Corneli AL, McKenna K, Headley J, **Ahmed K**, Odhiambo J, **Skhosana J**, Wang M and Agot K for the FEM-PrEP Study Group. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who

- seroconverted in Bondo, Kenya, and Pretoria, South Africa **Journal of the International AIDS Society** 2014, 17 (Suppl 2): 19152
18. Evens E, Tolley E, Headley J, McCarragher D, Hartmann M, Mtimkulu VT, **Manenzhe K**, Hamela G, Zulu F. Identifying factors that influence pregnancy intentions: evidence from South Africa and Malawi. **Culture, Health and Sexuality** 2014; 29: 1-16.
  19. Grant R.M, Liegler T, Defechreux P, Kashuba A.D.M, Taylor D, Abdel-Mohsen M., Deese J, Fransen K, De Baestelier I, Cricitti T, Bentley G, Agingu W, **Ahmed K** and Van Damme L. Drug resistance and plasma viral RNA level after ineffective use of pre-exposure prophylaxis in Women. **AIDS** 2014; 29 (3): 331-337.
  20. Headly J, Corneli A., Agot K, **Ahmed K**, Wang M, Odhiambo J, **Skhosana J**, Tharaldson J, van Damme L, MacQueen K, For the FEM-PrEP Study Group. The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa. **PloS One** 2014; 17: 9 (9).
  21. Corneli AL, Deese J, Wang M, Taylor D, **Ahmed K**, Agot K, Lombaard J, Monangi R, Kapiga S, Kashuba A and van Damme L, for the FEM-PrEP Study Group. FEM-PEP Adherence Patterns and Factors Associated with Adherence to a Daily oral Study Product for Pre-exposure Prophylaxis. **Journal of Acquired Immune Deficiency Syndromes** 2014; 66 (3): 324-331.
  22. Schenk KD, Friedland BA, Chau M, Stoner M, Plagianos MG, Skoler-Karpoff S, Palanee T, **Ahmed K**, Rathlagana MJM , Mthembu PN , and Ngcozela N. Enrollment of Adolescents Aged 16-17 Years Old in Microbicide Trials: An Evidence-Based Approach. **Journal of Adolescent Health** 2014; 54 (6): 654-662.
  23. **Malahleha M**, Mokwena K, **Ahmed K**. Knowledge and Perceptions of Vaginal Microbicides among Healthcare Postgraduate Students at the University of Limpopo. **AIDS Res Hum Retroviruses** 2014; 30 (S1): A163-A164.
  24. Mack N, Kirkendale S, Omullo P, Odhiambo J, Masiki M, Siguntu P, Rathlagana M, Agot K, **Ahmed K**, Kapiga S, Lombaard J, van Damme L, Corneli A. Implementing good participatory practice guidelines in the FEM-PrEP Preexposure Prophylaxis Trial for HIV Prevention Among African Women: a focus on local stakeholder involvement. **Journal of clinical Trials** 2013; 5:127-135.
  25. **Ahmed K**, Malahleha M, Deese J, Monedi C and van Damme L. Elevated liver transaminases, human immune deficiency virus (HIV) seroconversion and rapid progression to AIDS in a HIV prevention clinical trial participant: A case report **Journal of AIDS and HIV Research** 2013; 5 (3): 65-69.

26. Van Damme L, Corneli A, **Ahmed K**, Agot K, Lombaard J, Kapiga S, **Malahleha M** al. Pre-exposure prophylaxis for HIV infection among African women. **The New England Journal of Medicine** 2012; 367: 411-422.
27. Morrison C, Skoler-Karpoff S, Kwoka C, Chena P L, Wijgert J, Gehret-Plagianos MPatel S, Ahmed K, et al. Hormonal Contraception and the Risk of HIV Acquisition among Women in South Africa. **AIDS** 2012; 4: 497-504.
28. Marais Gawarecki D, Allan B, **Ahmed K**, Altini L, **Cassim N**, Gopaleng F, Hoffman M, Ramjee G, Williamson A-L. The Effectiveness of Carraguard, a Vaginal Microbicide, in protecting women against high-risk Human Papilloma-Virus infection. **Antiviral therapy** 2011; 16 (8): 1219-1226.
29. Mensch BS, Hewett PC, Abbott S, Rankin J, Littlefield S, **Ahmed K**, **Cassim N**, Patel S, Ramjee G, Palanee T, Mierzwa S, Skoler-Karpoff S. Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa: An Interview Mode Experiment Using a Placebo Gel. **AIDS and Behaviour** 2011; 15: 407-421.
30. Said HM, **Ahmed K**, Burnett R, Allan BR, Williamson A-L, Hoosen, AA. HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community based Microbicide study in Pretoria, South Africa. **Journal of Clinical Virology** 2009; 44: 318-321.
31. Skoler-Karpoff S, Ramjee G, **Ahmed K**, Altini L, GehretPlagianos M, Friedland B, Govender S, De Kock A, **Cassim N**, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomized, double-blind, placebo-controlled trial. **Lancet** 2008. 372:1977-1987.
32. **Ahmed K**, **Cassim N**. HIV prevention using vaginal microbicides: an update. **JIMASA** 2007; 14: 11-14.
33. de Kock A, Skoler S, **Ahmed K**, Govender S. Enrolling Adolescents in Research on HIV: Young Women Must Be Included. **PLoS Med** 2006; 3 (12): 2458-2463.
34. SkolerS, Govender S, Altini L, **Ahmed K**, Waldron D, Myer L, Lahteenmaki P, Fleming Richardson B. Risks in the use of an unblinded-control group. **Journal of Infectious Diseases** 2005; 191: 1378-1380.
35. Skoler S, Govender S, Altini L, **Ahmed K**, Waldron D, Myer L, Lahteenmaki P. Control Groups in Microbicide Trials: In defense of Orthodoxy. Correspondence Article. **Journal of Infectious Diseases** 2005; 191: 1378-1379.